KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

PRIMOLUT 250 MG/ML 2 ML INJECTION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

250 MG/ML 2 ML

 

GENERIC NAME:

HYDROXYPROGESTERONE CAPROATE

 

MANUFACTURER:

SCHERING AG

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

D

 

INDICATIONS:

 

SIDE EFFECTS:

ovarian enlargement or ovarian cyst formation

pain, redness, or skin irritation at the site of injection or implantation

unusual tiredness or weakness

unusual or rapid weight gain

vomiting

Acne

breast pain or tenderness

hot flashes

insomnia

libido decrease

loss or gain of body, facial, or scalp hair

melasma

nausea

Adrenal suppression or insufficiency or hypotension

delayed return of fertility in females

Amenorrhea

breakthrough menstrual bleeding or metromenorrhagia

hyperglycemia

menorrhagia

spotting

Galactorrhea

mental depression

skin rash

Adrenal suppression or insufficiency or hypotension

Cushing's syndrome

thromboembolism or thrombus formation

Abdominal pain or cramping

diarrhea

dizziness

drowsiness

edema

fatigue

headache, mild

mood changes

nausea

nervousness

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Thromboembolic disorders, including cerebrovascular disease, pulmonary embolism, retinal thrombosis

Thrombophlebitis

Asthma

Cardiac insufficiency, significant

Epilepsy

Hypertension

Migraine headaches

Renal dysfunction, significant

CNS disorders, such as depression or convulsions

Diabetes mellitus

Hepatic disease or dysfunction

Hyperlipidemia

Significant risk factors for low bone mineral content

 

ADULT DOSE:

Amenorrhea or Dysfunctional uterine bleeding- Intramuscular, 375 mg. Estrogen production, endogenous, diagnosis or Menses, induction of- Intramuscular, 125 to 250 mg given on Day 10 of the menstrual cycle, repeated every seven days until suppression is no longer desired. Note: Withdrawal bleeding usually occurs within three to seven days after discontinuing therapy.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT